King Pharmaceuticals KG Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Silvercrest Asset Management GroupSAMG

——

LazardLAZ

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's cash and cash equivalents, end of period?: King Pharmaceuticals (KG) reported cash and cash equivalents, end of period of $61.46M in Q1 2026.
How has King Pharmaceuticals's cash and cash equivalents, end of period changed year-over-year?: King Pharmaceuticals's cash and cash equivalents, end of period increased by 1702.3% year-over-year, from $3.41M to $61.46M.